secwatch.observer — SEC 8-K summary
======================================

Issuer:     HERON THERAPEUTICS, INC. /DE/ (HRTX)
CIK:        0000818033
Form:       8-K
Filed at:   2023-08-14T23:59:59+00:00
Accession:  0000950170-23-042414
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Heron Therapeutics Q2 2023 revenue up; secures $80M in new financing; cost cuts expected to save $75M through 2025
--------------------------------------------------------------------------------

- Oncology care franchise net product sales $27.3M (Q2 2023) vs $25.1M (Q2 2022); acute care franchise sales $4.5M vs $2.5M.
- Full-year 2023 oncology care net product sales guidance reiterated at $99M-$103M.
- Closed $29.7M equity placement in July 2023; entered $50M working capital facility in August 2023 with $24.5M drawn.
- Cost reduction program expected to save ~$75M in cash spend through 2025; new management team in place.
- Favorable Markman hearing outcome in CINVANTI patent litigation against Fresenius Kabi.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/818033/000095017023042414/0000950170-23-042414-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/818033/000095017023042414/hrtx-20230814.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-042414

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer